Fundraising Fox
Amgen Europe
NASDAQ: AMGNventure arm · Amgen VenturesAcquiredThousand Oaks, US · Founded 1980 · Delaware corporation · 12 known investors
Find your way into Amgen Europe
Sign up to see every warm intro you have to Amgen Europe
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amgen Europe team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Amgen January 2011 · $425M (up to $1 billion ($425M cash at closing plus up to $575M in milestones; $407M actual cash disclosed)) · source ↗
Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Founders & leadership
Amgen Europe was founded in 1980 by Sanford Markowitz, William K. Bowes, and George B. Rathmann.
Investors · 12
How we know: Asset Management Company's portfolio page · Not right? Tell us
How we know: CWRU Technology Ventures's portfolio page · Not right? Tell us
How we know: Mayfield Fund's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: US Venture Partners's portfolio page · Not right? Tell us
How we know: Ysios Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$14.3M disclosed across 2 of 3 rounds · 2011–2018
▶$8.9MraisedApr 2020 · 9 investors · BiotechnologyRule 506(b)
- Kendall MohlerExecutive Officer
- Margarita ChavezDirector
- Katie HewittDirector
- Thong LeExecutive Officer, Director, Promoter
- Tadataka YamadaDirector
- Asish XavierDirector
- Suzanne RettenmierExecutive Officer
- Sanford MarkowitzDirector
- Ian HowesExecutive Officer
- Steve GillisDirector
- Offering amount
- $8.9M
- Amount sold
- $8.9M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.4MraisedAug 2017 · 8 investors · BiotechnologyRule 506(b)
- Asish XavierDirector
- Steve GillisDirector
- Thong LeExecutive Officer, Director, Promoter
- David SchubertExecutive Officer, Promoter
- Sanford MarkowitzDirector
- James SullivanDirector
- Lindsay RayleExecutive Officer, Promoter
- Joel MarcusDirector
- Tadataka YamadaDirector
- Offering amount
- $5.9M
- Amount sold
- $5.4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.5BofferedJan 2015 · 34 investors · BiotechnologyRule 506(b)
- David PiacquadExecutive Officer
- Francois de CarbonnelDirector
- Brian M. McNameeExecutive Officer
- Tyler JacksDirector
- Ronald D. SugarDirector
- Robert A. BradwayExecutive Officer, Director
- David J. ScottExecutive Officer
- Madhavan BalachandranExecutive Officer
- Stuart A. TrossExecutive Officer
- David W. MelineExecutive Officer
- Sean E. HarperExecutive Officer
- Rebecca M. HendersonDirector
- Judith PelhamDirector
- Vance D. CoffmanDirector
- David BaltimoreDirector
- Cynthia M. PattonExecutive Officer
- Greg C. GarlandDirector
- Frank C. HerringerDirector
- Frank J. Biondi, Jr.Director
- Robert A. EckertDirector
- Anthony C. HooperExecutive Officer
- R. Sanders WilliamsDirector
- Offering amount
- $2.5B
- Minimum investment
- $250K
- Sales commissions
- $750K
- Placement agents
- Deutsche Bank Securities Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Banc of America Securities LLC, Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated
- First sale
- Sep 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 3
Early investors' stakes continue via these dealsFive Prime Therapeutics was a clinical-stage biotech in South San Francisco developing protein- and antibody-based immuno-oncology therapies, including the FGFR2b-targeting antibody bemarituzumab for gastric cancer.
Micromet was a biopharmaceutical company based in Rockville, MD and Munich, Germany that developed antibody-based cancer therapies using its proprietary BiTE (Bispecific T-cell Engager) platform, including lead candidate blinatumomab.
Nuevolution was a Copenhagen-based biopharmaceutical company developing small-molecule drugs for oncology and chronic inflammatory diseases using its proprietary DNA-encoded chemical library platform, Chemetics.
Frequently asked questions
- What does Amgen Europe do?
- Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
- Who founded Amgen Europe?
- Amgen Europe was founded by Sanford Markowitz, William K. Bowes, George B. Rathmann in 1980.
- Who are Amgen Europe's investors?
- Amgen Europe's investors include Asset Management Company, BOM, Boulder Ventures, CWRU Technology Ventures, Industrifonden, Mayfield Fund, Ridgeback Capital, US Venture Partners and 4 more.
- How much funding has Amgen Europe raised?
- Amgen Europe has disclosed $14.3M raised across 2 of its 3 known rounds.
- Where is Amgen Europe headquartered?
- Amgen Europe is headquartered in Thousand Oaks, US.